人工智能驱动的肿瘤浸润淋巴细胞空间分析作为非小细胞肺癌免疫检查点抑制的补充生物标志物
研究开发人工智能驱动的全切片图像分析器,将肿瘤微环境中肿瘤浸润淋巴细胞分为炎症型、免疫排斥型和免疫荒漠型三种免疫表型,并在两个独立晚期非小细胞肺癌队列中与免疫检查点抑制剂疗效和生存相关。炎症型与局部免疫细胞溶解活性富集、更高缓解率和更长无进展生存相关。
要点
- 人工智能模型判定的肿瘤比例评分与病理学家判定的对照肿瘤比例评分呈显著正相关(P < .001)。
- 44.0%肿瘤为炎症型,37.1%为免疫排斥型,18.9%为免疫荒漠型。
- 程序性死亡配体-1肿瘤比例评分<1%、1%-49%、≥50%患者中炎症型发生率分别为31.7%、42.5%、56.8%。
核心结论
- 人工智能驱动的肿瘤浸润淋巴细胞空间分析与晚期非小细胞肺癌免疫检查点抑制剂的肿瘤缓解和无进展生存相关。
- 该分析可能作为病理学家判定的肿瘤比例评分的补充生物标志物。
研究设计与样本
- 开发人工智能驱动的全切片图像分析器,定义炎症型、免疫排斥型和免疫荒漠型三种免疫表型。
- 在两个独立的晚期非小细胞肺癌患者队列中分析免疫表型与免疫检查点抑制剂肿瘤缓解和生存的相关性。
主要发现
- 炎症型免疫表型与局部免疫细胞溶解活性富集、更高缓解率和更长无进展生存相关,相比免疫排斥型或免疫荒漠型患者。
- 全切片图像水平上,人工智能模型判定的肿瘤比例评分与病理学家分析的对照肿瘤比例评分呈显著正相关(P < .001)。
- 总体44.0%肿瘤为炎症型,37.1%为免疫排斥型,18.9%为免疫荒漠型。
- 程序性死亡配体-1肿瘤比例评分<1%、1%-49%、≥50%患者中炎症型免疫表型发生率分别为31.7%、42.5%、56.8%。
- 炎症型免疫表型的中位无进展生存期和总生存期分别为4.1个月和24.8个月,免疫排斥型分别为2.2个月和14.0个月,免疫荒漠型分别为2.4个月和10.6个月。
关键数值与推荐
- 炎症型免疫表型与免疫排斥型或免疫荒漠型相比,缓解率更高、无进展生存期更长。
- 人工智能模型判定的肿瘤比例评分与病理学家判定的对照肿瘤比例评分显著正相关(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Biomarkers on the basis of tumor-infiltrating lymphocytes (TIL) are potentially valuable in predicting the effectiveness of immune checkpoint inhibitors (ICI). However, clinical application remains challenging because of methodologic limitations and laborious process involved in spatial analysis of TIL distribution in whole-slide images (WSI). METHODS: We have developed an artificial intelligence (AI)-powered WSI analyzer of TIL in the tumor microenvironment that can define three immune phenotypes (IPs): inflamed, immune-excluded, and immune-desert. These IPs were correlated with tumor response to ICI and survival in two independent cohorts of patients with advanced non-small-cell lung cancer (NSCLC). RESULTS: Inflamed IP correlated with enrichment in local immune cytolytic activity, higher response rate, and prolonged progression-free survival compared with patients with immune-excluded or immune-desert phenotypes. At the WSI level, there was significant positive correlation between tumor proportion score (TPS) as determined by the AI model and control TPS analyzed by pathologists (P < .001). Overall, 44.0% of tumors were inflamed, 37.1% were immune-excluded, and 18.9% were immune-desert. Incidence of inflamed IP in patients with programmed death ligand-1 TPS at < 1%, 1%-49%, and ≥ 50% was 31.7%, 42.5%, and 56.8%, respectively. Median progression-free survival and overall survival were, respectively, 4.1 months and 24.8 months with inflamed IP, 2.2 months and 14.0 months with immune-excluded IP, and 2.4 months and 10.6 months with immune-desert IP. CONCLUSION: The AI-powered spatial analysis of TIL correlated with tumor response and progression-free survival of ICI in advanced NSCLC. This is potentially a supplementary biomarker to TPS as determined by a pathologist.
引用
- Park S, Ock CY, Kim H, et al. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. J Clin Oncol. 2022. PMID: 35271299. doi:10.1200/JCO.21.02010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。